Previous 10 | Next 10 |
Following the Completion of the Transition of GLASSIA Manufacturing, Kamada will Transfer the Product’s US Biologics License Application (BLA) to Takeda; Expected to Occur by End of 2021 Kamada to Receive from Takeda a Payment of $2 Million for the BLA Transfer Fi...
It has been several years since we last did an in-depth piece on Israeli-based biotech concern Kamada. Early Wednesday, the company disclosed trial results on a candidate being evaluated as a potential treatment for COVID-19. Given that, it seems a good time to revisit this 'off t...
Kamada (KMDA) perks up 3% premarket after announcing top-line results from its Phase 1/2 open-label trial in Israel of its anti-SARS-CoV-2 plasma-derived hyperimmune globulin (IgG) treatment for COVID-19. Interim results were announced in September 2020. As previously reported, 11 o...
As Previously Reported, 11 of the 12 Patients Recovered and were Discharged from Hospital; Seven Patients were Discharged at or Before Day 5 and the Remaining Four Patients were Discharged by Day 9 of Treatment No Infusion-Related Reactions or Adverse Events Considered Related...
REHOVOT, Israel, March 09, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ and TASE: KMDA), a plasma-derived biopharmaceutical company, announced today that Amir London, Chief Executive Officer, will present a corporate overview at the inaugural Jefferies Virtual Global Plasma Summit, being he...
Transaction Furthers Kamada’s Strategic Objective to Evolve into a Fully Integrated Specialty Plasma Company Kamada is Already Actively Engaged in the Expansion of the Center’s Collection Capacity; Planning to Open Additional Plasma Collection Centers ...
The National Institutes of Health has halted a clinical trial evaluating the safety and effectiveness of COVID-19 convalescent plasma in emergency room patients with mild to moderate symptoms of COVID-19.Following a second planned interim analysis of the trial data, an independent d...
REHOVOT, Israel, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2020, with the U.S. Securities and Exchange Commissio...
Kamada (NASDAQ: KMDA ) announces preliminary Q4 and FY 2018 revenues. More news on: Kamada Ltd, Healthcare stocks news, Read more ...
Full-Year 2018 Revenue Expected to be Between $113 Million and $115 Million Anticipated Revenues Exceed Current Revenue Guidance of $102 Million to $108 Million Expected Full-Year 2018 Total Revenue Would Represent Increase of Between 10% and 12% Over Full-Year 2017 Revenue ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-17 17:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-17 04:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...